Eisai to increase Belviq sales force

Share this article:
More reps may be needed to propel sales for Belviq
More reps may be needed to propel sales for Belviq

In an announcement Tuesday, Arena Pharmaceuticals said that Eisai will double the number of reps marketing weight-loss drug Belviq. The increased sales force of 200 contract reps will bring the total number of sales people touting the prescription slimmer to around 400 by December.

Arena said that the expanded sales team will allow Eisai to reach around 65,000 physicians, and reps will be approaching primary care doctors and endocrinologists among others.

Although Tuesday's announcement cites increased payer and PBM coverage as a reason for the sales push, the ramp-up also happens to follow a September 30 research note in which an analyst said the drug needed more bodies promoting it.

Despite alarms over obesity, the prescription weight-loss drug market has been a slow build. Some marketers have told MM&M that one of the challenges is that obesity is where depression was decades ago, and that the market needs to cultivate the perception that obesity is a disease that can be treated.

Meanwhile, although payers have been signing on, it's a movement that is still gaining momentum, and investors have repeatedly said a lackluster sales-force push is part of the problem. Both Eisai and competitor Vivus have been criticized for depending on too few people to promote their products.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.